Allarity Therapeutics (ALLR) Stock Price, News & Analysis

Company Overview

Allarity Therapeutics (NASDAQ:ALLR) is a clinical-stage biotechnology company focusing on the development of precision oncology therapies through the use of predictive biomarkers. Founded in 2017 and headquartered in Copenhagen, Denmark, with an R&D hub near Boston, Allarity was formed through the merger of several Danish biotech ventures. The company’s core strategy involves revitalizing late‐stage oncology assets by pairing them with proprietary biomarker assays to identify patient populations most likely to respond.

The company’s lead asset, Zepsyre (formerly PM00104), is an alkylating agent under investigation in platinum‐resistant ovarian cancer. Allarity has initiated multiple Phase II clinical trials in Europe and North America, employing a companion diagnostic to enrich for responders and accelerate clinical development. Alongside Zepsyre, Allarity is advancing additional biomarker‐guided programs in endometrial and uterine cancers, leveraging its platform to move assets efficiently through the clinic.

Allarity’s business model centers on in-licensing or acquiring compounds with established safety profiles and applying its biomarker expertise to streamline development and reduce risk. The company collaborates with leading academic cancer centers and contract research organizations to support patient recruitment and trial execution across key geographies, including the European Union and the United States. Its proprietary assays are designed to offer a precision medicine approach, potentially improving response rates and shortening development timelines.

Under the leadership of CEO Peter Buhl Jensen, Allarity Therapeutics combines scientific, clinical and commercial expertise to advance its oncology pipeline. The management team includes seasoned professionals in drug development, diagnostics and regulatory affairs, positioning Allarity to pursue partnerships and regulatory interactions as it aims to bring personalized cancer therapies to patients in need.

Key Stats

• Today's Range: $0.98 to $1.06
• 50-Day Range: $0.80 to $1.10
• 52-Week Range: $0.61 to $7.45
• Volume: 366,432 shs
• Average Volume: 1.14 million shs
• Market Capitalization: $15.23 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Allarity Therapeutics Stock Analysis - MarketRank™

Allarity Therapeutics scored higher than 13% of companies evaluated by MarketBeat, and ranked 920th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Allarity Therapeutics.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Allarity Therapeutics are expected to grow in the coming year, from ($78.08) to ($46.85) per share.

Price to Book Value per Share Ratio

Allarity Therapeutics has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.54% of the float of Allarity Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Allarity Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Allarity Therapeutics has recently increased by 33.32%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Allarity Therapeutics does not currently pay a dividend.

Dividend Growth

Allarity Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.54% of the float of Allarity Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Allarity Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Allarity Therapeutics has recently increased by 33.32%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.37

News Sentiment

Allarity Therapeutics has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Allarity Therapeutics this week, compared to 4 articles on an average week.

Search Interest

3 people have searched for ALLR on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Allarity Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Allarity Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.08% of the stock of Allarity Therapeutics is held by insiders.

Percentage Held by Institutions

Only 11.53% of the stock of Allarity Therapeutics is held by institutions.

ALLR Stock Analysis - Frequently Asked Questions

How have ALLR shares performed this year?

Allarity Therapeutics' stock was trading at $1.17 on January 1st, 2025. Since then, ALLR shares have decreased by 13.7% and is now trading at $1.01.

How were Allarity Therapeutics' earnings last quarter?

Allarity Therapeutics, Inc. (NASDAQ:ALLR) announced its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($8.10) by $7.85.

When did Allarity Therapeutics' stock split?

Allarity Therapeutics's stock reverse split on Wednesday, September 11th 2024.The 1-30 reverse split was announced on Wednesday, September 11th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 10th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How will Allarity Therapeutics' stock buyback program work?

Allarity Therapeutics' Board of Directors initiated a share repurchase plan on Monday, March 3rd 2025, which allows the company to repurchase $5,000,000 in shares, according to EventVestor. This means that the company could reacquire up to 128.1% of its shares through open market purchases. Shares buyback plans are often an indication that the company's board of directors believes its shares are undervalued.

How do I buy shares of Allarity Therapeutics?

Shares of ALLR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Allarity Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Allarity Therapeutics investors own include AMC Entertainment (AMC), Plug Power (PLUG), Adial Pharmaceuticals (ADIL), Cara Therapeutics (CARA), Chemomab Therapeutics (CMMB), Finch Therapeutics Group (FNCH) and Nuwellis (NUWE).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/13/2025
• Next Earnings (Estimated): 8/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ALLR
• CIK: 1860657
• Web: www.allarity.com
• Phone: 401-426-4664
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$24.51 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -147.94%
• Return on Assets: -90.33%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.66
• Quick Ratio: 2.66

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.62 per share
• Price / Book: 0.62

Miscellaneous

• Outstanding Shares: 15,080,000
• Free Float: 15,068,000
• Market Cap: $15.23 million
• Optionable: Not Optionable
• Beta: 0.04